Skip to main content
Top
Published in: Intensive Care Medicine 3/2009

01-03-2009 | Original

Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough

Authors: Alejandro Rodriguez, Thiago Lisboa, Stijn Blot, Ignacio Martin-Loeches, Jorge Solé-Violan, Diego De Mendoza, Jordi Rello, Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators

Published in: Intensive Care Medicine | Issue 3/2009

Login to get access

Abstract

Background

It remains uncertain why immunocompetent patients with bacterial community-acquired pneumonia (CAP) die, in spite of adequate antibiotics.

Methods

This is a secondary analysis of the CAPUCI database which was a prospective observational multicentre study. Two hundred and twelve immunocompetent patients admitted to 33 Spanish ICUs for CAP were analyzed. Comparisons were made for lifestyle risk factors, comorbidities and severity of illness. ICU mortality was the principal outcome variable.

Results

Bacteremic CAP (43.3 vs. 21.1%) and empyema (11.5 vs. 2.2%) were more frequent (P < 0.05) in patients with Streptococcus pneumoniae CAP. Higher rates of adequate empiric therapy (95.8 vs. 75.5%, P < 0.05) were observed in patients with S. pneumoniae CAP. Patients with non-pneumococcal CAP experienced more shock (66.7 vs. 50.8%, P < 0.05), and need for mechanical ventilation (83.3 vs. 61.5%, P < 0.05). ICU mortality was 20.7 and 28% [OR 1.49(0.74–2.98)] among immunocompetent patients with S. pneumoniae (n = 122) and non-pneumococci (n = 90), in spite of initial adequate antibiotic. Multivariable regression analysis in these 184 immunocompetent patients with adequate empirical antibiotic treatment identified the following variables as independently associated with mortality: shock (HR 13.03); acute renal failure (HR 4.79), and APACHE II score higher than 24 (HR 2.22).

Conclusions

Mortality remains unacceptably high in immunocompetent patients admitted to the ICU with bacterial pneumonia, despite adequate initial antibiotics and comorbidities management. Patients with shock, acute renal failure and APACHE II score higher than 24 should be considered for inclusion in trials of adjunctive therapy in order to improve CAP survival.
Appendix
Available only for authorised users
Literature
1.
go back to reference Restrepo MI, Jorgensen JH, Mortensen EM, Anzueto A (2001) Severe community-acquired pneumonia: current outcomes, epidemiology, etiology and therapy. Curr Opin Infect Dis 14:703–709PubMed Restrepo MI, Jorgensen JH, Mortensen EM, Anzueto A (2001) Severe community-acquired pneumonia: current outcomes, epidemiology, etiology and therapy. Curr Opin Infect Dis 14:703–709PubMed
2.
go back to reference Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, Schultze-Werninghaus G (2005) Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 128:2238–2246PubMedCrossRef Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, Schultze-Werninghaus G (2005) Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 128:2238–2246PubMedCrossRef
3.
go back to reference Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A (2008) A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133:610–617PubMedCrossRef Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A (2008) A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133:610–617PubMedCrossRef
4.
go back to reference Lujan M, Gallego M, Rello J (2006) Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med 32:971–980PubMedCrossRef Lujan M, Gallego M, Rello J (2006) Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med 32:971–980PubMedCrossRef
5.
go back to reference Rello J, Rodriguez R, Jubert P, Alvarez B (1996) Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 23:723–728PubMed Rello J, Rodriguez R, Jubert P, Alvarez B (1996) Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 23:723–728PubMed
6.
go back to reference Restrepo MI, Anzueto A (2006) The role of new therapies for severe community-acquired pneumonia. Curr Opin Infect Dis 19:557–564PubMedCrossRef Restrepo MI, Anzueto A (2006) The role of new therapies for severe community-acquired pneumonia. Curr Opin Infect Dis 19:557–564PubMedCrossRef
7.
go back to reference Frei CR, Restrepo MI, Mortensen EM, Burgess DS (2006) Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 119:854–871CrossRef Frei CR, Restrepo MI, Mortensen EM, Burgess DS (2006) Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 119:854–871CrossRef
8.
go back to reference Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, de la Torre MV, Sirvent JM, Bodi M (2006) Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 27:1210–1216PubMedCrossRef Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, de la Torre MV, Sirvent JM, Bodi M (2006) Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 27:1210–1216PubMedCrossRef
9.
go back to reference Blot SI, Rodriguez A, Sole-Violan J, Blanquer J, Almirall J, Rello J (2007) Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 35:2509–2514PubMedCrossRef Blot SI, Rodriguez A, Sole-Violan J, Blanquer J, Almirall J, Rello J (2007) Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 35:2509–2514PubMedCrossRef
10.
go back to reference Rello J, Catalan M, Diaz E, Bodi M, Alvarez B (2002) Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 28:1030–1035PubMedCrossRef Rello J, Catalan M, Diaz E, Bodi M, Alvarez B (2002) Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 28:1030–1035PubMedCrossRef
11.
go back to reference Waterer GW, Kessler LA, Wunderink RG (2006) Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 130:11–15PubMedCrossRef Waterer GW, Kessler LA, Wunderink RG (2006) Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 130:11–15PubMedCrossRef
12.
go back to reference Bodi M, Rodriguez A, Sole-Violan J, Gilavert MC, Garnacho J, Blanquer J, Jimenez J, de la Torre MV, Sirvent JM, Almirall J, Doblas A, Badia JR, Garcia F, Mendia A, Jorda R, Bobillo F, Valles J, Broch MJ, Carrasco N, Herranz MA, Rello J (2005) Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 41:1709–1716PubMedCrossRef Bodi M, Rodriguez A, Sole-Violan J, Gilavert MC, Garnacho J, Blanquer J, Jimenez J, de la Torre MV, Sirvent JM, Almirall J, Doblas A, Badia JR, Garcia F, Mendia A, Jorda R, Bobillo F, Valles J, Broch MJ, Carrasco N, Herranz MA, Rello J (2005) Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 41:1709–1716PubMedCrossRef
13.
go back to reference Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, Valles J (2003) Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 123:174–180PubMedCrossRef Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, Valles J (2003) Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 123:174–180PubMedCrossRef
14.
go back to reference Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31:347–382PubMedCrossRef Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31:347–382PubMedCrossRef
16.
go back to reference Marik P, Varon J (1998) The hemodynamic derangements in sepsis: implications for treatments strategies. Chest 114:854–860PubMedCrossRef Marik P, Varon J (1998) The hemodynamic derangements in sepsis: implications for treatments strategies. Chest 114:854–860PubMedCrossRef
17.
go back to reference Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF, PROWESS Clinical Evaluation Committee (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952–961PubMedCrossRef Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF, PROWESS Clinical Evaluation Committee (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952–961PubMedCrossRef
18.
go back to reference Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J (2007) Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30:951–956PubMedCrossRef Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J (2007) Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30:951–956PubMedCrossRef
19.
go back to reference Gorman SK, Slavik RS, Marin J (2007) Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 41:1233–1237PubMedCrossRef Gorman SK, Slavik RS, Marin J (2007) Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 41:1233–1237PubMedCrossRef
20.
go back to reference Wunderink RG, Waterer GW (2004) Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 18:743–759PubMedCrossRef Wunderink RG, Waterer GW (2004) Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 18:743–759PubMedCrossRef
22.
go back to reference Waterer GW, Somes GW, Wunderink RG (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842PubMedCrossRef Waterer GW, Somes GW, Wunderink RG (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842PubMedCrossRef
23.
go back to reference Waterer GW, Rello J (2006) Choosing the right combination therapy in severe community-acquired pneumonia. Crit Care 10:115PubMedCrossRef Waterer GW, Rello J (2006) Choosing the right combination therapy in severe community-acquired pneumonia. Crit Care 10:115PubMedCrossRef
24.
go back to reference Waterer GW, Buckingham SC, Kessler LA, Quasney MW, Wunderink RG (2003) Decreasing beta-lactam resistance in Pneumococci from the Memphis region: analysis of 2,152 isolates from 1996 to 2001 Chest 124:519–525 Waterer GW, Buckingham SC, Kessler LA, Quasney MW, Wunderink RG (2003) Decreasing beta-lactam resistance in Pneumococci from the Memphis region: analysis of 2,152 isolates from 1996 to 2001 Chest 124:519–525
25.
go back to reference Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, Rello J, CAPUCI Study Group (2007) Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35:1493–1498PubMedCrossRef Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, Rello J, CAPUCI Study Group (2007) Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35:1493–1498PubMedCrossRef
27.
go back to reference Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB (2003) High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 37:752–760PubMedCrossRef Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB (2003) High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 37:752–760PubMedCrossRef
28.
go back to reference Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodríguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRef Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodríguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRef
29.
go back to reference Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG (2004) Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 164:637–644PubMedCrossRef Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG (2004) Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 164:637–644PubMedCrossRef
30.
go back to reference Hoste EAJ, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA (2006) RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 10:R73PubMedCrossRef Hoste EAJ, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA (2006) RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 10:R73PubMedCrossRef
31.
go back to reference Rodríguez A, Rello J (2008) Assessment of severity in patients with community-acquired pneumonia. Intensive Care Med 34:968CrossRef Rodríguez A, Rello J (2008) Assessment of severity in patients with community-acquired pneumonia. Intensive Care Med 34:968CrossRef
32.
go back to reference Waterer GW, Kessler LA, Wunderink RG (2004) Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 169:910–914PubMedCrossRef Waterer GW, Kessler LA, Wunderink RG (2004) Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 169:910–914PubMedCrossRef
33.
go back to reference Roberts JA, Lipman J (2006) Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 45:755–773PubMedCrossRef Roberts JA, Lipman J (2006) Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 45:755–773PubMedCrossRef
34.
go back to reference Shorr AF, Wunderink R (2008) There is no “CAP” on the importance of community-acquired pneumonia in the ICU. Chest 133:590–592PubMedCrossRef Shorr AF, Wunderink R (2008) There is no “CAP” on the importance of community-acquired pneumonia in the ICU. Chest 133:590–592PubMedCrossRef
35.
go back to reference Restrepo MI, Bienen T, Mortensen EM, Anzueto A, Metersky ML, Escalante P, Wunderink RG, Mangura BT (2008) Evaluation of ICU admission criteria and diagnostic methods for patients with severe community-acquired pneumonia: current practice survey. Chest 133:828–829PubMedCrossRef Restrepo MI, Bienen T, Mortensen EM, Anzueto A, Metersky ML, Escalante P, Wunderink RG, Mangura BT (2008) Evaluation of ICU admission criteria and diagnostic methods for patients with severe community-acquired pneumonia: current practice survey. Chest 133:828–829PubMedCrossRef
Metadata
Title
Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough
Authors
Alejandro Rodriguez
Thiago Lisboa
Stijn Blot
Ignacio Martin-Loeches
Jorge Solé-Violan
Diego De Mendoza
Jordi Rello
Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 3/2009
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-008-1363-6

Other articles of this Issue 3/2009

Intensive Care Medicine 3/2009 Go to the issue